1-(苯磺酰基)-1H-吲哚-4-胺 | 100557-22-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(苯磺酰基)-1H-吲哚-4-胺
• 英文名称: 1-(benzenesulfonyl)indol-4-amine
• 英文别名: 1-(phenylsulfonyl)-1H-indol-4-amine
• CAS: 100557-22-0
• 化学式: C₁₄H₁₂N₂O₂S
• 分子量: 272.327
• InChiKey: XQPCIFQSPLEMHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  73.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(苯磺酰基)-1H-吲哚-4-胺 在 4-二甲氨基吡啶 、 叔丁基锂 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 正戊烷 为溶剂， 反应 2.75h， 生成 (4-amino-1H-indol-2-yl)(4-methyl-1H-indol-2-yl)methanone
  参考文献：
  名称：

  A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia

  摘要：

  Mutants of the FLT3 receptor tyrosine kinase (RTK) with duplications in the juxtamembrane domain (FLT3-ITD) act as drivers of acute myeloid leukemia (AML). Potent tyrosine kinase inhibitors (TKi) of FLT3-ITD entered clinical trials and showed a promising, but transient success due to the occurrence of secondary drug-resistant AML clones. A further caveat of drugs targeting FLT3-ITD is the co-targeting of other RTKs which are required for normal hematopoiesis. This is observed quite frequently. Therefore, novel drugs are necessary to treat AML effectively and safely. Recently bis(1H-indol-2-yl)methanones were found to inhibit FLT3 and PDGFR kinases. In order to optimize these agents we synthesized novel derivatives of these methanones with various substituents. Methanone 16 and its carbamate derivative 17b inhibit FLT3-ITD at least as potently as the TKi AC220 (quizartinib). Models indicate corresponding interactions of 16 and quizartinib with FLT3. The activity of 16 is accompanied by a high selectivity for FLT3-ITD. (c) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112232
• 作为产物：
  描述：

  1-benzenesulfonyl-5-chloro-4-oxo-4,5,6,7-tetrahydroindole 在 ammonium acetate 、 溶剂黄146 作用下， 以 xylene 为溶剂， 反应 2.5h， 以92%的产率得到1-(苯磺酰基)-1H-吲哚-4-胺
  参考文献：
  名称：

  Matsumoto, Masakatsu; Ishida, Yasuko; Hatanaka, Naoto, Heterocycles, 1986, vol. 24, # 6, p. 1667 - 1674

  摘要：

  DOI：

文献信息

• [EN] SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS<br/>[FR] SYNTHÈSE, PHARMACOLOGIE ET UTILISATION DE NOUVEAUX INHIBITEURS SÉLECTIFS DE LA TYROSINE KINASE 3 DE TYPE FMS FLT3 (FLT3)
  申请人：UNIV REGENSBURG

  公开号：WO2019034538A1

  公开（公告）日：2019-02-21

  The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.

  本发明涉及式(I)的小分子化合物及其作为FLT3抑制剂用于治疗各种疾病，如急性髓系白血病（AML）。本发明还涉及合成这些化合物的方法和治疗方法。
• [EN] TETRAHYDROISOQUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE TÉTRAHYDROISOQUINOLINE
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2016055479A1

  公开（公告）日：2016-04-14

  The present invention relates to tetrahydroisoquinoline derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.

  本发明涉及公式（I）所示的四氢异喹啉衍生物，它们是D1的正向变构调节剂，因此在D1受体发挥作用的疾病治疗中作为药物剂有益。
• [EN] AROMATIC HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AROMATIQUES ET LEURS APPLICATIONS PHARMACEUTIQUES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2016004882A1

  公开（公告）日：2016-01-14

  Provided herein are aromatic heterocyclic derivatives or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof used for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and use of such compounds or pharmaceutical compositions thereof for managing or treating 5-HT6 receptor-mediated diseases, especially in the manufacture of a medicament for managing or treating Alzheimer's disease.

  本文提供了用于治疗阿尔茨海默病的芳香杂环衍生物或其立体异构体、互变异构体、N-氧化物、溶剂合物、代谢物、药用可接受盐或其前药。本文还提供了含有这些化合物的药物组合物，以及利用这些化合物或药物组合物管理或治疗5-HT6受体介导的疾病，特别是在制造用于管理或治疗阿尔茨海默病的药物的过程中。
• [EN] NOVEL TETRAYDROSPIRO{PIPERIDINE-2,7' -PYRROLO[3,2-b]PYRIDINE DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS<br/>[FR] NOUVEAUX DERIVES TETRAHYDROSPIRO{PIPERIDINE-2,7'-PYRROLO[3,2-B]PYRIDINE ET NOUVEAUX DERIVES INDOLE UTILES POUR LE TRAITEMENT DES TROUBLES ASSOCIES AU RECEPTEUR 5-HT6
  申请人：BIOVITRUM AB

  公开号：WO2005037834A1

  公开（公告）日：2005-04-28

  The present invention relates to compounds of formula (I): Formula (I) wherein U, P, W1, W2, W3, v, Y, Z, Rm, and Rm’ are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

  本发明涉及式(I)的化合物：式(I)其中U、P、W1、W2、W3、v、Y、Z、Rm和Rm'如本文所述，以及包含这些化合物的药物组合物，用于其制备的方法，以及用于制备针对5-HT6受体相关疾病的药物的化合物的用途。
• [EN] ISOINDOLINE DERIVATIVES<br/>[FR] DÉRIVÉS D'ISOINDOLINE
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2016055482A1

  公开（公告）日：2016-04-14

  The present invention relates to isoindoline derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.

  本发明涉及式(I)所示的异吲哚啉衍生物，它们是D1的正向变构调节剂，因此作为药用剂对D1受体在其中发挥作用的疾病具有益处。